A detailed history of O'Brien Greene & Co. Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, O'Brien Greene & Co. Inc holds 6,304 shares of BMY stock, worth $352,708. This represents 0.09% of its overall portfolio holdings.

Number of Shares
6,304
Previous 6,108 3.21%
Holding current value
$352,708
Previous $331,000 21.15%
% of portfolio
0.09%
Previous 0.11%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$40.25 - $52.99 $7,889 - $10,386
196 Added 3.21%
6,304 $261,000
Q4 2023

Feb 02, 2024

SELL
$48.48 - $57.85 $14,640 - $17,470
-302 Reduced 4.71%
6,108 $313,000
Q3 2023

Nov 08, 2023

SELL
$57.89 - $64.73 $8,683 - $9,709
-150 Reduced 2.29%
6,410 $372,000
Q2 2023

Aug 15, 2023

SELL
$63.71 - $70.74 $835,875 - $928,108
-13,120 Reduced 66.67%
6,560 $420,000
Q2 2023

Jul 20, 2023

BUY
$63.71 - $70.74 $815,742 - $905,754
12,804 Added 186.21%
19,680 $1.26 Million
Q4 2022

Feb 02, 2023

SELL
$68.48 - $81.09 $1.09 Million - $1.29 Million
-15,852 Reduced 69.75%
6,876 $495,000
Q3 2022

Nov 09, 2022

BUY
$0.13 - $76.84 $1,969 - $1.16 Million
15,152 Added 200.0%
22,728 $1.62 Million
Q2 2022

Aug 11, 2022

BUY
$72.62 - $79.98 $13,362 - $14,716
184 Added 2.49%
7,576 $583,000
Q1 2022

May 18, 2022

SELL
$61.48 - $73.72 $2,090 - $2,506
-34 Reduced 0.46%
7,392 $540,000
Q4 2021

Feb 08, 2022

SELL
$53.63 - $62.52 $9,867 - $11,503
-184 Reduced 2.42%
7,426 $463,000
Q1 2021

May 12, 2021

BUY
$59.34 - $66.74 $71,208 - $80,088
1,200 Added 18.72%
7,610 $480,000
Q4 2020

Feb 04, 2021

BUY
$57.74 - $65.43 $370,113 - $419,406
6,410 New
6,410 $398,000
Q1 2020

May 07, 2020

SELL
$46.4 - $67.43 $147,969 - $215,034
-3,189 Closed
0 $0
Q4 2019

Feb 05, 2020

BUY
$49.21 - $64.19 $156,930 - $204,701
3,189 New
3,189 $205,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $119B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track O'Brien Greene & Co. Inc Portfolio

Follow O'Brien Greene & Co. Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of O'Brien Greene & Co. Inc, based on Form 13F filings with the SEC.

News

Stay updated on O'Brien Greene & Co. Inc with notifications on news.